In a groundbreaking study published in BMC Cancer, researchers have unveiled significant associations between plasma levels of microRNAs miR-9 and miR-106a and the development of peritoneal carcinomatosis (PC) in patients suffering from gastric cancer (GC). This revelation may open new avenues for non-invasive diagnostics and prognostic evaluations in a cancer subtype infamous for its poor outcomes and challenging treatment course.

Peritoneal carcinomatosis, characterized by the widespread dissemination of cancer cells within the peritoneal cavity, remains a fatal complication in gastric cancer. Early and accurate diagnosis is critical yet remains fraught with difficulty due to the invasive nature of current methods and limitations in sensitivity. This recent study sought to bypass these hurdles by exploring the utility of circulating microRNAs—small, non-coding RNA molecules implicated in gene regulation—as biomarkers detectable in the bloodstream.

At the heart of this investigation was the rigorous optimization of a quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assay, tailored specifically to quantify plasma concentrations of miR-9 and miR-106a among a panel of 11 candidate miRNA transcripts. This methodological refinement ensured precise and reliable detection, laying the foundation for subsequent comparative analyses between gastric cancer patients with peritoneal carcinomatosis (GC/PC) and those without peritoneal involvement (GC/NPC), alongside healthy control subjects.

.adsslot_v7M2wUXYqc{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_v7M2wUXYqc{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_v7M2wUXYqc{ width:320px !important; height:50px !important; } }

ADVERTISEMENT

Initial screening involved 13 matched pairs of GC/PC and GC/NPC patients, revealing a distinct divergent pattern in plasma miR-9 and miR-106a levels. Notably, miR-9 levels were significantly reduced in the GC/PC group, while miR-106a levels were markedly elevated, suggesting these miRNAs play opposing roles or reflect different pathophysiological mechanisms in PC progression. To robustly validate these findings, the cohort was expanded to include 30 pairs of patient groups and 35 healthy individuals, reaffirming the initial observations with strong statistical significance.

The diagnostic power of these miRNA biomarkers was interrogated using receiver operating characteristic (ROC) curve analyses. MiR-9 demonstrated an impressive area under the curve (AUC) of 0.776, with a sensitivity of 67.4% and a specificity of 93% in distinguishing GC/PC from GC/NPC patients. Meanwhile, miR-106a exhibited even higher discriminatory ability, with an AUC of 0.830, sensitivity of 72.1%, and specificity of 83.7%. These performances closely rivaled that of the serum tumor marker carbohydrate antigen 125 (CA125), a biomarker conventionally monitored in peritoneal malignancies.

Interestingly, the study confirmed that carcinoembryonic antigen (CEA), another commonly used serum marker, did not significantly differ between patient groups, signaling limitations in its clinical utility for PC detection. This underscores the critical need for novel and more reliable biomarkers, a niche that miR-9 and miR-106a evidently fulfill. No significant plasma level differences in these miRNAs were noted between GC/NPC patients and healthy controls, further emphasizing their specificity for peritoneal involvement.

Beyond diagnosis, the prognostic value of miR-9 and miR-106a was also illuminated through Kaplan–Meier survival analyses. Elevated plasma miR-106a levels correlated with notably poorer overall survival in GC/PC patients, indicated by a hazard ratio (HR) of 0.44. Conversely, reduced miR-9 levels were similarly associated with diminished survival outcomes (HR = 0.43). These survival associations highlight the dual role of these miRNAs—not only as diagnostic tools but also predictors of clinical trajectory and patient prognosis.

The molecular underpinnings driving these associations beckon further exploration. MiR-9 has been implicated in tumor suppression pathways and modulation of epithelial-mesenchymal transition (EMT), a critical step in metastatic dissemination, perhaps explaining its decreased plasma presence during advanced peritoneal spread. Conversely, miR-106a is frequently reported as an oncogenic microRNA, promoting cell proliferation and resistance to apoptosis, which could underlie its upregulation in the context of PC.

Methodologically, the study’s elaborate validation steps—including paired-sample analysis, inclusion of healthy controls, and integration of established tumor markers—contribute to the robustness of the conclusions. Furthermore, the sensitivity and specificity metrics achieved suggest clinical translatability, potentially enabling routine blood tests to aid in the early detection of peritoneal carcinomatosis among gastric cancer patients, thereby guiding timely intervention.

These findings propel the field beyond traditional imaging and invasive diagnostic techniques, lending substantial weight to the paradigm shift towards liquid biopsy approaches in oncology. The quest to finely delineate cancer’s molecular signatures via circulating biomarkers promises personalized medicine strategies with less patient burden and enhanced monitoring capabilities.

However, several challenges remain before implementation into clinical practice. The variability in miRNA extraction and quantification methods across laboratories necessitates standardized protocols to ensure reproducibility. Additionally, larger multicenter studies are warranted to validate these markers across diverse populations and cancer stages.

In sum, this pioneering research delineates plasma miR-9 and miR-106a as potent non-invasive biomarkers intricately linked to the pathogenesis and prognosis of peritoneal carcinomatosis in gastric cancer patients. The convergence of diagnostic precision and prognostic insight within these miRNAs heralds a promising horizon for improved patient stratification and management.

As the scientific community continues to unravel the molecular complexities of cancer, circulating miRNAs are rapidly emerging as a frontier in biomarker discovery. This study’s elegant integration of molecular assays and clinical correlation exemplifies the innovative spirit driving precision oncology. Future investigations expanding upon these findings could ultimately transform the clinical landscape for gastric cancer and metastatic disease surveillance.

Extraordinary in its potential impact, this research not only spotlights miR-9 and miR-106a as biomarkers but also ignites interest in their possible roles as therapeutic targets. Modulating the expression of these miRNAs might influence cancer progression, offering a two-pronged approach combining diagnosis and treatment.

In the challenging battle against gastric cancer, particularly its lethal peritoneal spread, such advances offer glimmers of hope. Harnessing the nuanced language of microRNAs circulating in blood may well become a cornerstone of personalized cancer care, dramatically improving detection accuracy, guiding treatment choices, and ultimately enhancing survival outcomes.

With a growing global burden of gastric cancer and its associated metastases, innovative diagnostic tools that are minimally invasive yet highly informative are urgently needed. The promise demonstrated by miR-9 and miR-106a signals a significant step forward in meeting this clinical imperative.

This research marks a transformative moment, exemplifying how detailed molecular analyses converge with clinical realities to redefine cancer diagnostics. As these miRNA biomarkers journey from bench to bedside, their integration holds the potential to revolutionize oncological practice, ultimately saving lives and improving the quality of care worldwide.

Subject of Research: Investigation of circulating plasma microRNAs miR-9 and miR-106a as non-invasive biomarkers for diagnosis and prognosis of peritoneal carcinomatosis in gastric cancer patients.

Article Title: The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer.

Article References:
Chen, Q., Yao, Z., Duan, J. et al. The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer. BMC Cancer 25, 1090 (2025). https://doi.org/10.1186/s12885-025-14427-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14427-y

Tags: associations between microRNAs and cancer outcomescancer biomarker discoverychallenges in peritoneal carcinomatosis treatmentcirculating microRNAs in cancerearly detection of gastric cancergastric cancer prognosisgene regulation in cancermiR-9 and miR-106a biomarkersnon-invasive cancer diagnosticsperitoneal carcinomatosis diagnosisplasma microRNAs in gastric cancerquantitative reverse-transcription PCR assay